A simple drug regimen could cut childhood deaths from sickle cell anaemia in Africa by testing whether hydroxyurea works safely with minimal medical supervision. Sickle cell anaemia is a common inherited blood disorder that causes severe pain, organ damage, and early death. In sub-Saharan Africa, where most affected children are born, the disease receives far less attention than HIV, malaria, or tuberculosis. Current treatment guidelines require frequent lab monitoring, which makes widespread use of the disease-modifying drug hydroxyurea impractical in resource-limited settings. The H-PRIME trial asks whether a simpler, weight-based dosing strategy can reduce mortality and improve quality of life without intensive oversight. If successful, this research could transform how sickle cell is managed across the continent. It would allow thousands of children to access a treatment that modifies the course of the disease, rather than just managing its complications. The trial also tests two additional interventions: adding co-trimoxazole to prevent bacterial infections beyond what penicillin alone achieves, and replacing standard malaria prevention with a more modern drug combination that may overcome resistance. Together, these three questions address the major causes of illness and death in children with sickle cell anaemia, offering a practical, scalable package of care that ministries of health could implement widely.
View original technical description
Sickle cell anaemia (SCA) is a common inherited condition that affects around 1% of all children born in much of sub-Saharan Africa. Without early diagnosis and appropriate treatment under-5 mortality in those affected is between 50 and 90%. As a result, through much of the continent SCA is responsible for between 5 and 16% of total under-5 mortality. These high levels of mortality could be reduced dramatically with simple treatments that include educating parents to recognise danger signs and seek emergency care, and by measures that protect against acute bacterial and malarial infections using vaccines and prophylactic antibiotic and anti-malarial drugs. Nevertheless, without specific treatments that modify the course of the disease, many of those affected will live lives that are characterized by frequent and recurrent bouts of severe illness that include acute and chronic pain and progressive multi-organ deterioration. Unlike diseases like HIV, malaria and tuberculosis, SCA does not enjoy a high profile in the eyes of the international community and remains widely neglected by ministries of health through much of sub-Saharan Africa. In the last few years, the increasing use of the disease-modifying drug hydroxyurea has shown promise in improving the lives of children born with SCA in Africa, but the level of medical oversight and laboratory monitoring required precludes its widespread use if local guidelines are to be followed. Through H-PRIME, we will address three key questions in the management of children with SCA in Africa today through a single large, efficient and pragmatic clinical trial. First, we will determine whether hydroxyurea, can be used safely and effectively to reduce mortality and improve the quality of life in survivors when administered pragmatically following a weight-band-based dosing strategy with minimal clinical and laboratory monitoring. Second, we will investigate whether better protection from bacterial infections in children with SCA can reduce all cause hospital admission and further reduce mortality. The current approach to the prevention of bacterial infections is through the use of oral penicillin. However, this is only effective against a narrow range of bacterial organisms, and we will therefore investigate whether the addition of a second agent, co-trimoxazole, could bring further benefits in the absence of harm. Finally, the current approach to the prevention of malaria infections relies on drugs that are associated with high levels of resistance. We will therefore investigate whether malaria prevention with a more modern and highly effective drug - dihidroartemisinin-piperaquine - could be used as an alternative, and that this will not cause harm in terms of side effects and the development of further drug resistance.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know